Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Theravance Biopharma (TBPH) Debt Ratio (2018 - 2022)

Historic Debt Ratio for Theravance Biopharma (TBPH) over the last 5 years, with Q2 2022 value amounting to 1.1.

  • Theravance Biopharma's Debt Ratio rose 2338.13% to 1.1 in Q2 2022 from the same period last year, while for Jun 2022 it was 1.1, marking a year-over-year increase of 2338.13%. This contributed to the annual value of 1.04 for FY2021, which is 2389.53% up from last year.
  • Theravance Biopharma's Debt Ratio amounted to 1.1 in Q2 2022, which was up 2338.13% from 1.11 recorded in Q1 2022.
  • Theravance Biopharma's Debt Ratio's 5-year high stood at 1.11 during Q1 2022, with a 5-year trough of 0.41 in Q4 2018.
  • Over the past 5 years, Theravance Biopharma's median Debt Ratio value was 0.75 (recorded in 2020), while the average stood at 0.76.
  • Its Debt Ratio has fluctuated over the past 5 years, first soared by 6700.21% in 2021, then skyrocketed by 728.56% in 2022.
  • Over the past 5 years, Theravance Biopharma's Debt Ratio (Quarter) stood at 0.41 in 2018, then skyrocketed by 36.81% to 0.56 in 2019, then skyrocketed by 49.18% to 0.84 in 2020, then rose by 23.9% to 1.04 in 2021, then rose by 5.99% to 1.1 in 2022.
  • Its last three reported values are 1.1 in Q2 2022, 1.11 for Q1 2022, and 1.04 during Q4 2021.